
    
      This is a double blind, randomized, parallel group, controlled, multicenter phase II study.

      60 patients will be enrolled and assigned to one of the 5 dose or control groups. Each study
      group will include 8 patients.

      Each patient will receive a total of 6 injections according to the dose of the assigned study
      group. The injections will be administered subcutaneously in the upper arm once every four
      weeks for 5 months, i.e. at days 1, 29, 57, 85, 113 and 141.

      The volume of each injection will be 0.5 ml in all groups.
    
  